Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Respiratory (Paediatric)
  6. Distal Intestinal Obstruction Syndrome (DIOS) , adhesional obstruction and severe constipation management in children with cystic fibrosis (646)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Distal Intestinal Obstruction Syndrome (DIOS) , adhesional obstruction and severe constipation management in children with cystic fibrosis (646)

Warning

Scope

Distal Intestinal Obstruction Syndrome (DIOS) , adhesional obstruction and severe constipation management in children with cystic fibrosis RHC Glasgow

Background

Patients with Cystic Fibrosis usually require to take pancreatic enzyme supplements with all foods in order to digest fat and protein in their diet. Even with optimal pancreatic enzyme replacement therapy, only up to 85% of all ingested fat may be successfully absorbed. Occasionally, stool fat content will increase over time, resulting in stool accumulation –in the distal ileum presenting as DIOS, or more generally throughout the colon presenting as severe constipation. Patients who are pancreatic sufficient may also present in this way. Children with cystic fibrosis who have had previous surgery (particularly a laparotomy in the neonatal period for meconium ileus) may have complications related to intraperitoneal adhesions.

Is the diagnosis DIOS, Adhesional Obstruction or Severe Constipation?

Constipation, DIOS and adhesional obstruction may occur in children with Cystic Fibrosis, and the presentation may be similar with degrees of abdominal pain, abdominal distension and obstipation. With DIOS and adhesional obstruction, there may be an acute onset of symptoms versus a more gradual onset of symptoms in constipation.

Imaging

In practice, the differential diagnosis of mild incomplete DIOS versus severe constipation may not always be possible to make clinically. Although an abdominal X-ray may help to clarify this by showing faecal accumulation predominantly in the right flank in DIOS, imaging may not be required as initial management of these conditions is similar 1,2.

However if there is concern that there may be complete intestinal obstruction - especially in children who have had previous abdominal surgery - eg a history of severe or worsening abdominal pain and / or vomiting – especially bilious - a plain abdominal x-ray (AXR) should be requested early. Dilated bowel loops +/- Intestinal fluid levels may support a diagnosis of complete DIOS with obstruction, or adhesional obstruction.

Distal Intestinal Obstruction Syndrome - DIOS

DIOS incidence varies widely (paediatric lifetime prevalence of ~8%) but it mostly affects those with pancreatic insufficiency. The pathophysiology is not fully understood, but there may be multiple contributory factors including:

  • Severe CF genotype
  • Pancreatic insufficiency
  • Inadequate salt intake
  • Dehydration
  • Poorly controlled fat malabsorption
  • History of meconium ileus as neonate or DIOS Post organ transplantation 2

ESPGHAN Working Group Definition of DIOS in CF 3

CRITERIA 

 

COMPLETE / OBSTRUCTED DIOS

INCOMPLETE DIOS

1

Complete intestinal obstruction as evidenced by vomiting of bilious material and/or fluid levels in small intestine on an abdominal radiograph

 

2

Faecal mass in ileo-caecum

3

Abdominal pain and/or distension

Incomplete DIOS - Mild / Severe

DIOS is associated with relatively acute onset of symptoms (days rather than weeks) .Thick faecal material accumulates in the terminal ileum leading to partial obstruction in incomplete DIOS. Symptoms may be mild or severe and include mild to moderate intermittent, peri-umbilical and/or right lower quadrant abdominal pain with nausea. There may be a palpable mass in the RIF. Children who have had previous surgery (particularly a laparotomy in the neonatal period for meconium ileus) may have complications related to intraperitoneal adhesions – close monitoring for developing signs of complete obstruction is required.

Management of  Mild / Severe Incomplete DIOS

Management is step-wise and will depend on severity of symptoms and response to treatment Stages 1-3.

If there is any concern that complete bowel obstruction has occurred a plain abdominal x-ray (AXR) is required. 

INCOMPLETE  DIOS- MANAGEMENT

Symptoms / Signs

Abdominal pain predominantly  right lower quadrant with abdominal fullness  +/-palpable mass right iliac fossa.
+/- previous history of DIOS.
+/- non-bilious infrequent vomiting
+/- diarrhoea

Mild
Incomplete DIOS

Stage 1

Ensure adequate hydration.

Faecal Disimpaction Protocol for up to 5 days with review. 

Stage 2

If symptoms persist despite Stage 1
Admit patient
Oral Gastrografin [see Formulary]- administer ASAP after admission.
Use for up to 3 days if no response in first 24 hours but not if symptoms worsen.

If symptoms do not respond to Stage 1&2 or patient cannot tolerate oral Gastrografin -treat as Severe Incomplete DIOS – Stage 3.

At all Stages, monitor for symptoms of Complete / Obstructed DIOS eg frequent or worsening vomiting (often bilious), worsening abdominal pain.

STAGE 1&2 Mild Incomplete DIOS Only- Oral N-acetylcysteine (NAC) – disulphide bond breaker may  be added to treatment- see Formulary

Severe Incomplete DIOS

Stage 3
Liaise with RHC GI Consultant
Check U+E; LFT; amylase; FBC; CRP
NG Klean Prep  [ see Formulary] 
Establish adequate analgesia [ see  Formulary ]
Aim is to take Klean Prep solution until clear fluid is passed PR. May require NG tube.

Monitor for symptoms of Complete /Obstructed DIOS eg frequent or worsening vomiting (often bilious), worsening abdominal pain. 

Complete / Obstructed DIOS

Complete/ Obstructed DIOS is characterised by abdominal distension, worsening abdominal pain (often colicky), frequent or worsening vomiting –often bilious - and bowel loop dilatation +/- fluid levels on AXR. Complete DIOS is rare in children, but a surgical opinion should be sought early and AXR requested if this is suspected or there is doubt about the differential diagnosis eg complex / complicated case due to previous abdominal surgery. In particular, signs of intestinal ischaemia should prompt immediate surgical referral. These include tachycardia, pyrexia, abdominal tenderness on palpation or percussion, and raised inflammatory markers.

COMPLETE  DIOS – MANAGEMENT

Symptoms / Signs

Abdominal pain -often colicky
Palpable mass right iliac fossa.
Bilious vomiting and / or AXR- dilated bowel loops +/- fluid levels 
Tenderness on abdominal palpation/percussion
Signs of intestinal ischaemia should prompt immediate surgical referral. These include tachycardia, pyrexia,abdominal tenderness on palpation or percussion, and raised inflammatory markers.

Management- Complete DIOS

Seek early Surgical advice.

NG tube is needed to empty the stomach and prevent biliousaspiration. Establish IV fluids.

Regular assessment by on-call surgical team with consideration of early operative management

Management of Severe Constipation

Constipation may occur over a period of time (weeks rather than days) and present with a history of generalized abdominal pain and infrequent, hard stools. Clinical examination may reveal faecal masses which are generally felt in the left iliac fossa. Vomiting is rare and non-bilious. 

Mild constipation can be managed with regular laxatives. If constipation is prolonged or severe the GGC Paediatric Disimpaction protocol may be required. There should be frequent review of the patient’s progress at home and re-assessment with AXR if signs of complete obstruction become evident. 

GGC Paediatric Disimpaction Protocol

Paediatric Movicol- 

  • 1-5 yrs 2 sachets on day 1, then 4 sachets for 2 days, then 6 sachets for 2 days and 8 sachets daily thereafter.
  • 5-12 yrs 4 sachets on day 1, then increase by 2 sachets daily until max of 12 sachets daily.
  • >12 yrs see adult regime(BNF)

If disimpaction not achieved by 2 weeks, add a stimulant laxative eg Senna. If Movicol is not tolerated, use Lactulose and Senna for disimpaction

Further Management

Following treatment for DIOS or Severe Constipation, Movicol Paediatric should be prescribed for ongoing home use:

Child 1–11 months
0.5–1 sachet daily.

Child 1 year
1 sachet daily, adjust dose to produce regular soft stools; maximum 4 sachets per day.

Child 2–5 years
1 sachet daily, adjust dose to produce regular soft stools; maximum 4 sachets per day.

Child 6–11 years
2 sachets daily, adjust dose to produce regular soft stools; maximum 4 sachets per day.

Dietetic Management

  • The CF dietitian should be informed of any cases of constipation, DIOS or adhesional obstruction requiring hospital admission.
  • A dietary assessment should be conducted and a review of pancreatic enzyme replacement therapy (PERT) initiated if there is evidence of under or over dosing of PERT.
  • Avoidance of dehydration is important to prevent future episodes occurring. Advice to maintain adequate fluid intake should also be given.

Pain Management

Oral regular paracetamol - doses as per BNFC 

For severe pain consider IV paracetamol for  24-48 hours- doses as per BNFC.  

Avoid/stop all opioid analgesia

FORMULARY

GASTROGRAFIN BNFC 2020

Distal intestinal obstruction syndrome in children with cystic fibrosis

By mouth

Child 1–23 months 
15–30 mL for 1 dose.

Child (body-weight 15–25 kg)
50 mL for 1 dose.

Child (body-weight 26 kg and above)
100 mL for 1 dose.

Directions for administration

Intravenous prehydration is essential in neonates and infants. Fluid intake should be encouraged for 3 hours after administration.

By mouth

  • for child bodyweight under 25 kg, dilute Gastrografin® with 3 times its volume of water or fruit juice; 
  • for child bodyweight over 25 kg, dilute Gastrografin® with twice its volume of water or fruit juice.

 

KLEAN PREP – BNFC 2020

Distal intestinal obstruction syndrome

By mouth, or by nasogastric tube, or by gastrostomy tube

Child 1–17 years

10 mL/kilogram/hour for 30 minutes, then increased to 20 mL/kilogram/hour for 30 minutes, then increased if tolerated to 25 mL/kilogram/hour, max. 100 mL/kg (or 4 litres) over 4 hours, repeat 4 hour treatment if necessary.

Directions for administration

1 sachet should be reconstituted with 1 litre of water.

Flavouring such as clear fruit cordials may be added if required.

After reconstitution the solution should be kept in a refrigerator and discarded if unused after 24 hours.

 

N-ACETYLCYSTEINE 

Oral N-acetylcysteine – Disulphide bond breaker.  

The 200mg/ml injection can be given orally and should be mixed with water, orange juice, blackcurrant juice or cola to a concentration of 50mg/ml. 
Alternatively, 200mg sachets or 600mg tablets are available. 
For larger doses consider the use of the IV preparation for oral administration to reduce the burden of volume

  • 1 month – 6 months: 0.4 g
  • 6-12 months: 1 g
  • 12-18 months: 1.6 g
  • 18m – 2 year: 2 g
  • 2-6 years: 3 g
  • 6-12 year: 4 g
  • >12 year:  6 g

Editorial Information

Last reviewed: 22/03/2021

Next review date: 01/03/2023

Author(s): Dr Jane Wilkinson, Dr Rachel Tayler, Mr Gregor Walker, Dr Tom Savage, Susan Kafka, Julie Crocker.

Version: 2

Approved By: Paediatric Drugs & Therapeutics Committee

References

1. Carla Colombo, Helmut Ellemunter, Roderick Houwen, Anne Munck, Chris Taylor, Michael Wilschanski on behalf of the ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. Journal of Cystic Fibrosis, Volume 10 Suppl 2 (2011) S24–S28.